FDA Public Hearing Today on Potential CBD Regulation
The agency is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol.
The Food and Drug Administration is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol. The public hearing will be held from 8 a.m. to 6 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, in Silver Spring, Md.
FDA had announced the hearing on April 2, saying it would also accept electronic or written comments until July 2, 2019. Visit www.regulations.gov and search for docket number FDA-2019-N-1482 to file a comment.
The agency also formed an internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed, including consideration of what statutory or regulatory changes might be needed and what the public health impact of that marketing would be.